The Latest Cardiac and Vascular News
Medical imaging AI companies collaborate to offer CINA-iPE on TeraRecon’s Eureka Clinical AI platform. CAMBRIDGE, Mass., March 13, 2023 /PRNewswire/ — ConcertAI’s TeraRecon, the advanced visualization and AI Clinical SaaS category leader, today announced a partnership to offer medical imaging AI specialist Avicenna.AI‘s CINA-iPE solution detecting the presence of incidental pulmonary embolisms as part of […]
Internationally Recognized and Awarded Interventional Radiologist Enhances Depth of Expertise as the LIBERTY® Robotic System Races Towards Regularity and Commercialization Objectives HINGHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to experience a rising interest in the LIBERTY ® Robotic System, the first single-use endovascular robotic […]
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing Windtree that it has […]
Pivotal study expected to be completed by year-end 2023 and set the stage for commercialization of PerQseal® system for large hole vessel closure Company announces €30 million strategic investment from Haemonetics as part of its previously disclosed Series D financing GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical® Limited (“Vivasure” or the “Company”), a company pioneering novel […]
The last patient included in the study has completed the final protocol follow-up visit. The first results of the study will be released before the end of the first half of 2023, after the database is frozen and the statistical analysis work is completed. This international, multicenter Phase II/III study […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for […]
— Full results from ELPIS I trial published in European Heart Journal Open – — First patient to be randomized in Japan Aging-Related Phase 2 study in Q1 – — Conference call scheduled for 8:30 a.m. ET today — MIAMI, March 10, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) […]
Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of sales growth in 2023 PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive […]
CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In […]
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second quarter of 2023 – – Published results […]
